Skip to content

Capsule Endoscopy in Obscure GI Bleeding

An Economic Evaluation of Capsule Endoscopy for Obscure Gastrointestinal Bleeding

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00203619
Enrollment
40
Registered
2005-09-20
Start date
2005-05-31
Completion date
2016-09-30
Last updated
2017-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obscure Gastrointestinal Bleeding

Brief summary

The purpose of this study is to conduct a cost-effectiveness analysis of wireless capsule endoscopy in the investigation of patients with overt obscure gastrointestinal bleeding. To inform this analysis, a randomized controlled trial of capsule endoscopy compared with standard care will be conducted

Detailed description

The purpose of this study is to conduct a cost-effectiveness analysis of wireless capsule endoscopy in the investigation of patients with overt obscure gastrointestinal bleeding. To inform this analysis, a randomized controlled trial of capsule endoscopy compared with standard care will be conducted. Patients randomized 1:1.

Interventions

wire less capsule endoscopy

OTHERstandard care

standard diagnostic evaluation as decided by treating physician

Sponsors

Alberta Heritage Foundation for Medical Research
CollaboratorOTHER
Calgary Health Region
CollaboratorOTHER
University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 18 or older 2. Obscure overt GI bleeding 3. No cause for bleeding found on Gastroscopy and colonoscopy within 1 week of bleeding

Exclusion criteria

1. Known or suspected swallowing disorders 2. Known or suspected small bowel obstruction 3. Multiple comorbidities precluding surgery 4. Patients with implantable electromagnetic devices 5. Pregnant women

Design outcomes

Primary

MeasureTime frame
sf3648 weeks
giqli48 weeks
eq5048 weeks
diagnostic yield48 weeks

Secondary

MeasureTime frame
transfusions48 weeks

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026